Illumina will provide clinical sequencing services to Florida State University’s new Diagnostic Lab for Pediatric Rare Diseases, aiming to accelerate rare disease diagnostics for an estimated 30 million affected Americans.
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
VolitionRx reports its lateral flow prototype can detect nucleosomes in finger-prick blood samples from sepsis patients, enabling rapid, point-of-care testing outside centralized labs, according to company data.
SYNERGEN Health has launched IGNITE, an AI-driven revenue cycle management platform for laboratories, designed to address denied claims and delayed reimbursements.
LifeTracDx blood test will evaluate PD-L1 expression changes as exploratory biomarker in trial combining leronlimab with standard therapies.
